A 28-year-old man with atypical hemolytic uremic syndrome (aHUS) due to Factor H mutation presents with microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Plasma exchange has failed. Which drug targeting the complement system is the drug of choice for this patient?